By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Head Office
Technologielaan 3
Leuven    B - 3001  Belgium
Phone: 32-16-39-60-60 Fax: 32-16-39-60-70



Company News
TiGenix Announces Launch Of Proposed Initial Public Offering In The United States 12/6/2016 10:18:46 AM
TiGenix Shelves Nasdaq IPO Plans 10/27/2016 7:57:45 AM
TiGenix Publishes Transparency Notifications Pursuant To Article 14 Of The Law Of May 2, 2007 10/27/2016 7:22:12 AM
TiGenix Announces Orphan Drug Designation (ODD) For Cx601 In Switzerland 10/18/2016 10:14:59 AM
TiGenix Appoints Dr. June Almenoff To Its Board Of Directors 9/22/2016 9:47:21 AM
Takeda (TKPYY) And TiGenix Announce Publication In The Lancet Of 24-Week Results Of The Phase 3 ADMIRE-CD Trial Investigating Cx601 In The Treatment Of Complex Perianal Fistulas In Patients With Crohn's Disease 8/2/2016 6:42:44 AM
Cormorant Asset Management, LLC Notifies 5.81% Shareholding In TiGenix 7/20/2016 9:37:40 AM
TiGenix Reconfirms Its Strategic Focus On Its Allogeneic Stem Cell Platforms 7/5/2016 9:49:00 AM
TiGenix Lands $400 Million+ Crohn's Disease Deal with Pharma Giant Takeda (TKPYY) 7/5/2016 6:09:30 AM
TiGenix Announces Six-Month Phase I/II Results Of Allocsc-01 In Acute Myocardial Infarction 6/20/2016 11:30:00 AM